Home › Research › Biomarkers
Higher plasma β-synuclein indicates early synaptic degeneration in Alzheimer's disease
Patrick Oeckl, Shorena Janelidze, Steffen Halbgebauer, Erik Stomrud, Sebastian Palmqvist, Markus Otto, Oskar Hansson. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2023-04-27
Topic: Plasma and spinal-fluid biomarkers
Plasma β-synuclein levels were higher in preclinical AD and even higher in MCI and AD dementia. Stratification according to amyloid/tau pathology revealed higher β-synuclein in A+ T- and A+ T+ subjects compared with A- T- . Plasma β-synuclein levels were related to tau and Aβ pathology and associated with temporal cortical thinning and cognitive impairment. Our data indicate that plasma β-synuclein might track synaptic dysfunction, even during the preclinical stages of AD. HIGHLIGHTS: Plasma β-synuclein is already higher in preclinical AD. Plasma β-synuclein is higher in MCI and AD dementia than in preclinical AD. Aβ- and tau-PET SUVRs are associated with plasma β-synuclein levels. Plasma β-synuclein is already higher in tau-PET negative subjects. Plasma β-synuclein is related to temporal cortical atrophy and cognitive impairment.
Key findings
- Plasma β-synuclein levels were higher in preclinical AD and even higher in MCI and AD dementia.
- Stratification according to amyloid/tau pathology revealed higher β-synuclein in A+ T- and A+ T+ subjects compared with A- T- .
- Plasma β-synuclein levels were related to tau and Aβ pathology and associated with temporal cortical thinning and cognitive impairment.
- Our data indicate that plasma β-synuclein might track synaptic dysfunction, even during the preclinical stages of AD.
- HIGHLIGHTS: Plasma β-synuclein is already higher in preclinical AD.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants48
- Evidence strengthLow
How this study scored 52/100
Published in a leading specialty journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multi-centre collaboration and free to read, so those were left out: it earned 29 of the 56 points we could judge it on, which is 52 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia : the journal of the Alzheimer's Association) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 1 / 4 | 48 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 37186338) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 29 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 29 of the 56 points we could judge it on is 52 out of 100. |
| Total | 52 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
APA 7th
Oeckl, P., Janelidze, S., Halbgebauer, S., Stomrud, E., Palmqvist, S., Otto, M., et al. (2023). Higher plasma β-synuclein indicates early synaptic degeneration in Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1002/alz.13103
Vancouver
Oeckl P, Janelidze S, Halbgebauer S, Stomrud E, Palmqvist S, Otto M, et al. Higher plasma β-synuclein indicates early synaptic degeneration in Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2023. doi:10.1002/alz.13103. PMID: 37186338.
BibTeX
@article{oeckl2023-37186338,
author = {Oeckl, Patrick and Janelidze, Shorena and Halbgebauer, Steffen and Stomrud, Erik and Palmqvist, Sebastian and Otto, Markus and Hansson, Oskar},
title = {{Higher plasma β-synuclein indicates early synaptic degeneration in Alzheimer's disease}},
journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
year = {2023},
doi = {10.1002/alz.13103},
pmid = {37186338},
url = {https://doi.org/10.1002/alz.13103}
}
Related studies in Biomarkers
Also tagged “blood-based”
698 studies in the library carry the topic tag “blood-based”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 698 tagged studies.